BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33795686)

  • 1. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.
    Gualtieri A; Kyprianou N; Gregory LC; Vignola ML; Nicholson JG; Tan R; Inoue SI; Scagliotti V; Casado P; Blackburn J; Abollo-Jimenez F; Marinelli E; Besser REJ; Högler W; Karen Temple I; Davies JH; Gagunashvili A; Robinson ICAF; Camper SA; Davis SW; Cutillas PR; Gevers EF; Aoki Y; Dattani MT; Gaston-Massuet C
    Nat Commun; 2021 Apr; 12(1):2028. PubMed ID: 33795686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
    Inoue S; Moriya M; Watanabe Y; Miyagawa-Tomita S; Niihori T; Oba D; Ono M; Kure S; Ogura T; Matsubara Y; Aoki Y
    Hum Mol Genet; 2014 Dec; 23(24):6553-66. PubMed ID: 25035421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult mice expressing a Braf Q241R mutation on an ICR/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype.
    Moriya M; Inoue S; Miyagawa-Tomita S; Nakashima Y; Oba D; Niihori T; Hashi M; Ohnishi H; Kure S; Matsubara Y; Aoki Y
    Hum Mol Genet; 2015 Dec; 24(25):7349-60. PubMed ID: 26472072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras/MAPK dysregulation in development causes a skeletal myopathy in an activating Braf
    Maeda Y; Tidyman WE; Ander BP; Pritchard CA; Rauen KA
    Dev Dyn; 2021 Aug; 250(8):1074-1095. PubMed ID: 33522658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial cardio-facio-cutaneous syndrome: Vertical transmission of the BRAF p.G464R pathogenic variant and review of the literature.
    Rauen KA; Maeda Y; Egense A; Tidyman WE
    Am J Med Genet A; 2021 Feb; 185(2):469-475. PubMed ID: 33274568
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Aoidi R; Houde N; Landry-Truchon K; Holter M; Jacquet K; Charron L; Krishnaswami SR; Yu BD; Rauen KA; Bisson N; Newbern J; Charron J
    Dis Model Mech; 2018 Mar; 11(3):. PubMed ID: 29590634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is diagnosing cardio-facio-cutaneous (CFC) syndrome still a challenge? Delineation of the phenotype in 15 Polish patients with proven mutations, including novel mutations in the BRAF1 gene.
    Ciara E; Pelc M; Jurkiewicz D; Kugaudo M; Gieruszczak-Białek D; Skórka A; Posmyk R; Jakubiuk-Tomaszuk A; Cieślikowska A; Chrzanowska KH; Jezela-Stanek A; Krajewska-Walasek M
    Eur J Med Genet; 2015 Jan; 58(1):14-20. PubMed ID: 25463315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sibling pair with cardiofaciocutaneous syndrome (CFC) secondary to BRAF mutation with unaffected parents-the first cases of gonadal mosaicism in CFC?
    Geoghegan S; King G; Henchliffe J; Ramsden SC; Barry RJ; Green AJ; O'Connell SM
    Am J Med Genet A; 2018 Jul; 176(7):1637-1640. PubMed ID: 29704308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiofaciocutaneous syndrome, a Noonan syndrome related disorder: clinical and molecular findings in 11 patients].
    Carcavilla A; García-Miñaúr S; Pérez-Aytés A; Vendrell T; Pinto I; Guillén-Navarro E; González-Meneses A; Aoki Y; Grinberg D; Ezquieta B
    Med Clin (Barc); 2015 Jan; 144(2):67-72. PubMed ID: 25194980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome.
    Champion KJ; Bunag C; Estep AL; Jones JR; Bolt CH; Rogers RC; Rauen KA; Everman DB
    Clin Genet; 2011 May; 79(5):468-74. PubMed ID: 20735442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Braf induces esophageal dilation and gastric epithelial hyperplasia in mice.
    Inoue SI; Takahara S; Yoshikawa T; Niihori T; Yanai K; Matsubara Y; Aoki Y
    Hum Mol Genet; 2017 Dec; 26(23):4715-4727. PubMed ID: 28973166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.
    Urosevic J; Sauzeau V; Soto-Montenegro ML; Reig S; Desco M; Wright EM; Cañamero M; Mulero F; Ortega S; Bustelo XR; Barbacid M
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5015-20. PubMed ID: 21383153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-type natriuretic peptide improves growth retardation in a mouse model of cardio-facio-cutaneous syndrome.
    Inoue SI; Morozumi N; Yoshikiyo K; Maeda H; Aoki Y
    Hum Mol Genet; 2019 Jan; 28(1):74-83. PubMed ID: 30239744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
    Ueda K; Yaoita M; Niihori T; Aoki Y; Okamoto N
    Am J Med Genet A; 2017 Sep; 173(9):2346-2352. PubMed ID: 28650561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes.
    Tidyman WE; Rauen KA
    Methods Mol Biol; 2010; 661():433-47. PubMed ID: 20812000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.
    Siegel DH; McKenzie J; Frieden IJ; Rauen KA
    Br J Dermatol; 2011 Mar; 164(3):521-9. PubMed ID: 21062266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-485 deletion variant of BRAF may exhibit the severe end of the clinical spectrum of CFC syndrome.
    Suzuki-Muromoto S; Miyabayashi T; Nagai K; Yamamura-Suzuki S; Anzai M; Takezawa Y; Sato R; Okubo Y; Endo W; Inui T; Togashi N; Kikuchi A; Niihori T; Aoki Y; Kure S; Haginoya K
    J Hum Genet; 2019 May; 64(5):499-504. PubMed ID: 30842599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardio
    Chen B; Chen S; Xiong J; Yin F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Apr; 46(4):432-437. PubMed ID: 33967092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.
    Gripp KW; Lin AE; Nicholson L; Allen W; Cramer A; Jones KL; Kutz W; Peck D; Rebolledo MA; Wheeler PG; Wilson W; Al-Rahawan MM; Stabley DL; Sol-Church K
    Am J Med Genet A; 2007 Jul; 143A(13):1472-80. PubMed ID: 17551924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A transient myelodysplastic/myeloproliferative neoplasm in a patient with cardio-facio-cutaneous syndrome and a germline BRAF mutation.
    Sekiguchi K; Maeda T; Suenobu S; Kunisaki N; Shimizu M; Kiyota K; Handa YS; Akiyoshi K; Korematsu S; Aoki Y; Matsubara Y; Izumi T
    Am J Med Genet A; 2013 Oct; 161A(10):2600-3. PubMed ID: 23950000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.